knowledge -WSS

knowledge

author：hotspot 2025-10-06 08:57:41 Page View：51635

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Inaction leaves children at risk from dangerous chemotherapy drug
Next article： Guidelines to prevent youth baseball injuries need more muscle

knowledge

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

A single drug, study failures leave Anavex with nothing but cash

MollyFerguson/STATIttookAnavexLifeSciencessevenmonthstofinallyacknowledgethefailureofalate-stageclin

Affirmative action in medical school literally saved lives

AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

Prior authorization reform is both possible and imperative

AdobeImaginethisscene:Youareacancerpatientalreadynavigatingfearanduncertaintyaroundyourtreatment,whe

knowledge

explore

knowledge

Prior authorization reform is both possible and imperative